Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 41
Filter
1.
Bioorg Med Chem Lett ; 107: 129769, 2024 Jul 15.
Article in English | MEDLINE | ID: mdl-38670537

ABSTRACT

Among small-molecule CDK4/6 inhibitors (palbociclib, ribociclib, and abemaciclib) approved for metastatic breast cancers, abemaciclib has a more tolerable adverse effects in clinic. This is attributable to preferential inhibition of CDK4 over CDK6. In our search for a biased CDK4 inhibitor, we discovered a series of pyrimidine-indazole inhibitors. SAR studies led us to TQB3616 as a preferential CDK4 inhibitor. TQB3616 exhibited improvements in both enzymatic and cellular proliferation inhibitory potency when tested side-by-side with the FDA approved palbociclib and abemaciclib. TQB3616 also possessed favorable PK profile in multiple species. These differentiated properties, together with excellent GLP safety profile warranted TQB3616 moving to clinic. TQB3616 entered into clinical development in 2019 and currently in phase III clinical trials (NCT05375461, NCT05365178).


Subject(s)
Cell Proliferation , Cyclin-Dependent Kinase 4 , Protein Kinase Inhibitors , Cyclin-Dependent Kinase 4/antagonists & inhibitors , Cyclin-Dependent Kinase 4/metabolism , Humans , Protein Kinase Inhibitors/pharmacology , Protein Kinase Inhibitors/chemistry , Protein Kinase Inhibitors/chemical synthesis , Structure-Activity Relationship , Molecular Structure , Cell Proliferation/drug effects , Animals , Drug Discovery , Antineoplastic Agents/pharmacology , Antineoplastic Agents/chemistry , Antineoplastic Agents/chemical synthesis , Dose-Response Relationship, Drug , Pyrimidines/chemistry , Pyrimidines/pharmacology , Pyrimidines/chemical synthesis , Rats , Drug Screening Assays, Antitumor , Drug Evaluation, Preclinical
2.
Health Sci Rep ; 6(7): e1361, 2023 Jul.
Article in English | MEDLINE | ID: mdl-37404450

ABSTRACT

Background and Aims: The evolving mutants of SARS-CoV-2 have made the COVID-19 pandemic sustained for over 3 years. In 2022, BA.4 and BA.5 were the Omicron variants dominating the spread globally. Although COVID-19 was no longer a Public Health Emergency of International Concern (PHEIC) as announced by WHO, the SARS-CoV-2 variants remain a challenge to global healthcare under the circumstances of withdrawal and loosening of personal protective behavior in the post-quarantine era. This study aims to acknowledge the clinical characteristics caused by Omicron BA.4/BA.5 in COVID-19 naive people and analyze possible factors affecting disease severities. Methods: In this retrospective study, we report and analyze the clinical features of 1820 COVID-19 patients infected with the BA.4/BA.5 Omicron variants of SARS-CoV-2 during a local outbreak that occurred in Macao SAR, China, from June to July 2022. Results: A total of 83.5% of patients were symptomatic eventually. The most common symptoms were fever, cough, and sore throat. Hypertension, dyslipidemia, and diabetes mellitus were the leading comorbidities. There were significantly more elderly patients (p < 0.001), more patients with comorbidity (p < 0.001) and more patients without vaccination or not completing the series (p < 0.001) in the "Severe to Critical" group. All deceased patients were elderly with at least three comorbidities and were partial to totally dependent in their daily lives. Conclusion: Our data are consistent with a milder disease caused by BA.4/5 Omicron variants in the general population, while patients with old age and comorbidities have developed severe to critical diseases. Complete vaccination series and booster doses are effective strategies to reinforce protection against severe diseases and avoid mortality.

3.
Bioorg Med Chem Lett ; 66: 128734, 2022 06 15.
Article in English | MEDLINE | ID: mdl-35436589

ABSTRACT

We previously described the discovery of a novel indole series compounds as oral SERD for ER positive breast cancer treatment. Further SAR exploration focusing on substitutions on indole moiety of compound 12 led to the discovery of a clinical candidate LX-039. We report herein its profound anti-tumor activity, desirable ER antagonistic characteristics combined with favorable pharmacokinetic and preliminary safety properties. LX-039 is currently in clinical trial (NCT04097756).


Subject(s)
Breast Neoplasms , Receptors, Estrogen , Administration, Oral , Breast Neoplasms/drug therapy , Breast Neoplasms/pathology , Clinical Trials as Topic , Estrogen Receptor alpha , Female , Humans , Indoles/pharmacology , Indoles/therapeutic use , Selective Estrogen Receptor Modulators/pharmacology
4.
Bioorg Med Chem Lett ; 30(22): 127601, 2020 11 15.
Article in English | MEDLINE | ID: mdl-33035677

ABSTRACT

Most estrogen receptor positive (ER +) breast cancers depend on ER signaling pathway to develop. Clinical application of SERD fulvestrant effectively degraded ER, blocked its function and prolonged progression free survival of ER + breast cancer patients. However, current SERD suffers from limited bioavailability, therefore is given as intramuscular (IM) injection. In this paper, we report herein a novel indole series compounds with nanomolar range ER degradation potencies and oral systemic exposures. Selected compounds suppressed tumor growth in vivo in ER + MCF7 breast cancer CDX model via p.o. administration. All those data supported further optimizations of this analog to develop preclinical candidate as oral SERD for ER + breast cancer's treatment.


Subject(s)
Antineoplastic Agents/pharmacology , Breast Neoplasms/drug therapy , Drug Design , Indoles/pharmacology , Receptors, Estrogen/antagonists & inhibitors , Administration, Oral , Animals , Antineoplastic Agents/administration & dosage , Antineoplastic Agents/chemical synthesis , Breast Neoplasms/metabolism , Breast Neoplasms/pathology , Cell Proliferation/drug effects , Dose-Response Relationship, Drug , Drug Screening Assays, Antitumor , Female , Humans , Indoles/administration & dosage , Indoles/chemical synthesis , MCF-7 Cells , Mammary Neoplasms, Experimental/drug therapy , Mammary Neoplasms, Experimental/metabolism , Mammary Neoplasms, Experimental/pathology , Mice , Mice, Inbred BALB C , Molecular Structure , Receptors, Estrogen/metabolism , Structure-Activity Relationship
5.
Cancer Med ; 9(10): 3371-3382, 2020 05.
Article in English | MEDLINE | ID: mdl-32187883

ABSTRACT

Clofarabine is active in refractory/relapsed acute myeloid leukemia (AML). In this phase 2 study, we treated 18- to 65-year-old AML patients refractory to first-line 3 + 7 daunorubicin/cytarabine induction or relapsing after 3 + 7 induction and high-dose cytarabine consolidation, with clofarabine (30 mg/m2 /d, Days 1-5), cytarabine (750 mg/m2 /d, Days 1-5), and mitoxantrone (12 mg/m2 /d, Days 3-5) (CLAM). Patients achieving remission received up to two consolidation cycles of 50% CLAM, with eligible cases bridged to allogeneic hematopoietic stem cell transplantation (allo-HSCT). The mutational profile of a 69-gene panel was evaluated. Twenty-six men and 26 women at a median age of 46 (22-65) years were treated. The overall response rate after the first cycle of CLAM was 90.4% (complete remission, CR: 69.2%; CR with incomplete hematologic recovery, CRi: 21.2%). Twenty-two CR/CRi patients underwent allo-HSCT. The 2-year overall survival (OS), relapse-free survival (RFS), and event-free survival (EFS) were 65.8%, 45.7%, and 40.2%, respectively. Multivariate analyses showed that superior OS was associated with CR after CLAM (P = .005) and allo-HSCT (P = .005), and superior RFS and EFS were associated with allo-HSCT (P < .001). Remarkably, CR after CLAM and allo-HSCT resulted in 2-year OS of 84.3% and 90%, respectively. Karyotypic aberrations and genetic mutations did not influence responses or survivals. Grade 3/4 neutropenia/thrombocytopenia and grade 3 febrile neutropenia occurred in all cases. Other nonhematologic toxicities were mild and uncommon. There was no treatment-related mortality and the performance of allo-HSCT was not compromised. Clofarabine, cytarabine, and mitoxantrone was highly effective and safe in refractory/relapsed AML. This study was registered at ClinicalTrials.gov (NCT02686593).


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Drug Resistance, Neoplasm , Hematopoietic Stem Cell Transplantation , Leukemia, Myeloid, Acute/drug therapy , Adult , Aged , Chemotherapy-Induced Febrile Neutropenia/epidemiology , Clofarabine/administration & dosage , Cytarabine/administration & dosage , Disease-Free Survival , Female , Humans , Leukemia, Myeloid, Acute/genetics , Male , Middle Aged , Mitoxantrone/administration & dosage , Neoplasm Recurrence, Local , Survival Rate , Thrombocytopenia/chemically induced , Thrombocytopenia/epidemiology , Transplantation, Homologous , Young Adult
6.
Cancer ; 125(17): 3001-3012, 2019 09 01.
Article in English | MEDLINE | ID: mdl-31090936

ABSTRACT

BACKGROUND: Strategies using oral arsenic trioxide (As2 O3 ) are efficacious in relapsed acute promyelocytic leukemia (APL), but they have not been examined in newly diagnosed cases. METHODS: Sixty-two consecutive patients (24 men and 38 women) with a median age of 52 years (range, 22-85 years), 36% of whom had high-risk features, underwent induction with all-trans retinoic acid at 45 mg/m2 /d, oral As2 O3 at 10 mg/d, and ascorbic acid at 1 g/d (the all-trans retinoic acid-arsenic trioxide-ascorbic acid [AAA] regimen) for 6 weeks (with patients younger than 70 years additionally receiving daunorubicin at 50 mg/m2 /d × 3); they then underwent consolidation with 2 monthly cycles of daunorubicin (50 mg/m2 /d × 2) and cytarabine (100 mg/m2 /d × 5) and received AAA maintenance (2 weeks every 8 weeks) for 2 years. A contemporaneous cohort of 37 newly diagnosed patients (15 men and 22 women) with a median age of 51 years (range, 23-78 years), not consenting to oral As2 O3 induction but receiving similar induction, consolidation, and AAA maintenance, served as a comparator group; 46% of these patients had high-risk features. RESULTS: The oral As2 O3 induction cohort showed a complete remission (CR) rate of 100%. After a median of 37 months (range, 13-82 months), there were no relapses, so conventional risks (age, leukocyte and platelet counts, and Fms-like tyrosine kinase 3 [FLT3] mutations) were not relevant. The leukemia-free survival (LFS) and overall survival (OS) rates were 100% at 3 years and 94.1% at 5 years. The non-As2 O3 induction cohort showed a CR rate of 100%. After a median of 52 months (range, 14-77 months), there were 3 relapses (8%). Comparable patients in the oral As2 O3 induction and non-As2 O3 induction cohorts showed similar OS, but LFS was significantly superior in the oral As2 O3 induction cohort. CONCLUSIONS: The incorporation of oral As2 O3 into induction for newly diagnosed APL was safe and decreased relapses.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Leukemia, Promyelocytic, Acute/drug therapy , Administration, Oral , Adult , Aged , Aged, 80 and over , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Arsenic Trioxide/administration & dosage , Female , Humans , Leukemia, Promyelocytic, Acute/mortality , Male , Middle Aged , Prospective Studies , Treatment Outcome , Tretinoin/administration & dosage , Young Adult
7.
J Pharmacol Exp Ther ; 368(2): 299-307, 2019 02.
Article in English | MEDLINE | ID: mdl-30413627

ABSTRACT

Abdominal pain represents a significant complaint in patients with irritable bowel syndrome (IBS). While the etiology of IBS is incompletely understood, prior exposure to gastrointestinal inflammation or psychologic stress is frequently associated with the development of symptoms. Inflammation or stress-induced expression of growth factors or cytokines may contribute to the pathophysiology of IBS. Here, we aimed to investigate the therapeutic potential of inhibiting the receptor of glial cell line-derived neurotrophic factor, rearranged during transfection (RET), in experimental models of inflammation and stress-induced visceral hypersensitivity resembling IBS sequelae. In RET-cyan fluorescent protein [(CFP) RetCFP/+] mice, thoracic and lumbosacral dorsal root ganglia were shown to express RET, which colocalized with calcitonin gene-related peptide. To understand the role of RET in visceral nociception, we employed GSK3179106 as a potent, selective, and gut-restricted RET kinase inhibitor. Colonic hyperalgesia, quantified as exaggerated visceromotor response to graded pressures (0-60 mm Hg) of isobaric colorectal distension (CRD), was produced in multiple rat models induced 1) by colonic irritation, 2) following acute colonic inflammation, 3) by adulthood stress, and 4) by early life stress. In all the rat models, RET inhibition with GSK3179106 attenuated the number of abdominal contractions induced by CRD. Our findings identify a role for RET in visceral nociception. Inhibition of RET kinase with a potent, selective, and gut-restricted small molecule may represent a novel therapeutic strategy for the treatment of IBS through the attenuation of post-inflammatory and stress-induced visceral hypersensitivity.


Subject(s)
Colon/enzymology , Disease Models, Animal , Irritable Bowel Syndrome/enzymology , Protein Kinase Inhibitors/therapeutic use , Proto-Oncogene Proteins c-ret/antagonists & inhibitors , Proto-Oncogene Proteins c-ret/metabolism , A549 Cells , Animals , Cell Line, Tumor , Colon/drug effects , Female , Humans , Irritable Bowel Syndrome/drug therapy , Male , Mice , Mice, Transgenic , Pregnancy , Protein Kinase Inhibitors/pharmacology , Rats , Rats, Long-Evans , Rats, Sprague-Dawley
8.
Oncotarget ; 7(5): 5461-9, 2016 Feb 02.
Article in English | MEDLINE | ID: mdl-26701727

ABSTRACT

Hepatocellular carcinoma (HCC) is the fifth most common type of cancers worldwide. However, current therapeutic approaches for this epidemic disease are limited, and its 5-year survival rate hasn't been improved in the past decades. Patient-derived xenograft (PDX) tumor models have become an excellent in vivo system for understanding of disease biology and drug discovery. In order to identify new therapeutic targets for HCC, whole-exome sequencing (WES) was performed on more than 60 HCC PDX models. Among them, four models exhibited protein-altering mutations in JAK1 (Janus Kinase 1) gene. To explore the transforming capability, these mutations were then introduced into HEK293FT and Ba/F3 cells. The results demonstrated that JAK1S703I mutation was able to activate JAK-STAT (Signal Transducer and Activator of Transcription) signaling pathway and drive cell proliferation in the absence of cytokine stimulation in vitro. Furthermore,the sensitivity to the treatment of a JAK1/2 inhibitor, ruxolitinib, was observed in JAK1S703I mutant PDX model, but not in other non-activating mutant or wild type models. Pharmacodynamic analysis showed that phosphorylation of STAT3 in the Ruxolitinib-treated tumor tissues was significantly suppressed. Collectively, our results suggested that JAK1S703I is an activating mutation for JAK-STAT signaling pathway in vitro and in vivo, and JAK-STAT pathway might represent a new therapeutic approach for HCC treatment. Monotherapy using a more potent and specific JAK1 inhibitor and combinatory therapy should be further explored in JAK1 mutant PDX models.


Subject(s)
Carcinoma, Hepatocellular/drug therapy , Janus Kinase 1/genetics , Liver Neoplasms/drug therapy , Mutation/genetics , Pyrazoles/pharmacology , STAT3 Transcription Factor/antagonists & inhibitors , Animals , Apoptosis , Blotting, Western , Carcinoma, Hepatocellular/genetics , Carcinoma, Hepatocellular/pathology , Cell Proliferation , Female , Humans , Janus Kinase 1/antagonists & inhibitors , Liver Neoplasms/genetics , Liver Neoplasms/pathology , Mice , Mice, Inbred BALB C , Mice, Nude , Nitriles , Phosphorylation , Pyrimidines , RNA, Messenger/genetics , Real-Time Polymerase Chain Reaction , Reverse Transcriptase Polymerase Chain Reaction , STAT3 Transcription Factor/genetics , Signal Transduction , Tumor Cells, Cultured , Xenograft Model Antitumor Assays
9.
Hematology ; 21(1): 10-8, 2016 Jan.
Article in English | MEDLINE | ID: mdl-26292161

ABSTRACT

OBJECTIVE: To define the clinicopathologic features, outcome, and prognostic indicators of myelofibrosis (MF) in Asian patients. METHODS: Two hundred and seventy consecutive Chinese patients (primary MF, n = 207; post-polycythemia vera MF, n = 27; and post-essential thrombocythemia MF, n = 36) from seven regional referral hospitals were analyzed. RESULTS: The median overall survival (OS) for primary MF was 66 months. Multivariate analysis showed that age >65 years (P = 0.02), platelet count <100 × 10(9)/l (P = 0.001), and leukemic transformation (P = 0.001) negatively impacted on OS. The median OS of 63 patients with secondary MF was 44 months. In primary MF, the 10-year cumulative risk of leukemic transformation was 28%. On multivariate analysis, unfavorable karyotypes significantly predicted inferior leukemia-free survival (LFS) (P = 0.03). In secondary MF, the 10-year cumulative risk of leukemic transformation was 31%. Circulating blasts ≥1% significantly predicted inferior LFS (P = 0.04). The international prognostic scoring system (IPSS) and dynamic IPSS were not significant survival predictors in our cohort. Eighteen patients underwent allogeneic hematopoietic stem cell transplantation. The median OS post-transplantation was merely 19 months. DISCUSSION: Platelet count <100 × 10(9)/l, unfavorable karyotypes, and circulating blasts >1% were negative prognostic indicators. Conclusion Chinese MF patients were similar to Western patients in clinicopathologic features and outcome.


Subject(s)
Hematopoietic Stem Cell Transplantation , Polycythemia Vera/pathology , Primary Myelofibrosis/pathology , Thrombocythemia, Essential/pathology , Adult , Aged , Aged, 80 and over , Antineoplastic Agents/therapeutic use , Asian People , Bone Marrow/drug effects , Bone Marrow/pathology , China , Female , Follow-Up Studies , Humans , Male , Middle Aged , Multivariate Analysis , Platelet Count , Polycythemia Vera/complications , Polycythemia Vera/drug therapy , Polycythemia Vera/mortality , Primary Myelofibrosis/drug therapy , Primary Myelofibrosis/etiology , Primary Myelofibrosis/mortality , Prognosis , Survival Analysis , Thrombocythemia, Essential/drug therapy , Thrombocythemia, Essential/etiology , Thrombocythemia, Essential/mortality , Transplantation, Homologous , Treatment Outcome
10.
Oncotarget ; 6(24): 20160-76, 2015 Aug 21.
Article in English | MEDLINE | ID: mdl-26062443

ABSTRACT

Lack of clinically relevant tumor models dramatically hampers development of effective therapies for hepatocellular carcinoma (HCC). Establishment of patient-derived xenograft (PDX) models that faithfully recapitulate the genetic and phenotypic features of HCC becomes important. In this study, we first established a cohort of 65 stable PDX models of HCC from corresponding Chinese patients. Then we showed that the histology and gene expression patterns of PDX models were highly consistent between xenografts and case-matched original tumors. Genetic alterations, including mutations and DNA copy number alterations (CNAs), of the xenografts correlated well with the published data of HCC patient specimens. Furthermore, differential responses to sorafenib, the standard-of-care agent, in randomly chosen xenografts were unveiled. Finally, in the models expressing high levels of FGFR1 gene according to the genomic data, FGFR1 inhibitor lenvatinib showed greater efficacy than sorafenib. Taken together, our data indicate that PDX models resemble histopathological and genomic characteristics of clinical HCC tumors, as well as recapitulate the differential responses of HCC patients to the standard-of-care treatment. Overall, this large collection of PDX models becomes a clinically relevant platform for drug screening, biomarker discovery and translational research in preclinical setting.


Subject(s)
Carcinoma, Hepatocellular/genetics , Liver Neoplasms/genetics , Polymorphism, Single Nucleotide/genetics , Receptors, Fibroblast Growth Factor/genetics , Animals , Carcinoma, Hepatocellular/pathology , DNA Copy Number Variations , Disease Models, Animal , Female , Gene Expression , Genomics , Humans , Liver Neoplasms/pathology , Mice, Inbred BALB C , Mice, Nude , Mice, SCID , Xenograft Model Antitumor Assays
11.
BMC Genet ; 15: 147, 2014 Dec 20.
Article in English | MEDLINE | ID: mdl-25526816

ABSTRACT

BACKGROUND: Myeloproliferative neoplasms (MPNs) are a group of haematological malignancies that can be characterised by a somatic mutation (JAK2V617F). This mutation causes the bone marrow to produce excessive blood cells and is found in polycythaemia vera (~95%), essential thrombocythaemia and primary myelofibrosis (both ~50%). It is considered as a major genetic factor contributing to the development of these MPNs. No genetic association study of MPN in the Hong Kong population has so far been reported. Here, we investigated the relationship between germline JAK2 polymorphisms and MPNs in Hong Kong Chinese to find causal variants that contribute to MPN development. We analysed 19 tag single nucleotide polymorphisms (SNPs) within the JAK2 locus in 172 MPN patients and 470 healthy controls. Three of these 19 SNPs defined the reported JAK2 46/1 haplotype: rs10974944, rs12343867 and rs12340895. Allele and haplotype frequencies were compared between patients and controls by logistic regression adjusted for sex and age. Permutation test was used to correct for multiple comparisons. With significant findings from the 19 SNPs, we then examined 76 additional SNPs across the 148.7-kb region of JAK2 via imputation with the SNP data from the 1000 Genomes Project. RESULTS: In single-marker analysis, 15 SNPs showed association with JAK2V617F-positive MPNs (n = 128), and 8 of these were novel MPN-associated SNPs not previously reported. Exhaustive variable-sized sliding-window haplotype analysis identified 184 haplotypes showing significant differences (P < 0.05) in frequencies between patients and controls even after multiple-testing correction. However, single-marker alleles exhibited the strongest association with V617F-positive MPNs. In local Hong Kong Chinese, rs12342421 showed the strongest association signal: asymptotic P = 3.76 × 10-15, empirical P = 2.00 × 10-5 for 50,000 permutations, OR = 3.55 for the minor allele C, and 95% CI, 2.59-4.87. Conditional logistic regression also signified an independent effect of rs12342421 in significant haplotype windows, and this independent effect remained unchanged even with the imputation of additional 76 SNPs. No significant association was found between V617F-negative MPNs and JAK2 SNPs. CONCLUSION: With a large sample size, we reported the association between JAK2V617F-positive MPNs and 15 tag JAK2 SNPs and the association of rs12342421 being independent of the JAK2 46/1 haplotype in Hong Kong Chinese population.


Subject(s)
Asian People/genetics , Janus Kinase 2/genetics , Myeloproliferative Disorders/genetics , Polymorphism, Single Nucleotide , Adolescent , Adult , Aged , Aged, 80 and over , Case-Control Studies , DNA Mutational Analysis , Female , Genetic Association Studies , Genotype , Haplotypes , Hong Kong , Humans , Linkage Disequilibrium , Male , Middle Aged , Young Adult
12.
J Thorac Oncol ; 9(3): 285-94, 2014 Mar.
Article in English | MEDLINE | ID: mdl-24496003

ABSTRACT

INTRODUCTION: The aim of this study was to identify anaplastic lymphoma kinase (ALK) rearrangements in lung cancer patient-derived xenograft (PDX) models and to explore their responses to crizotinib. METHODS: Screening of 99 lung cancer PDX models by the NanoString ALK fusion assay identified two ALK-rearranged non-small-cell lung cancer (NSCLC) tumors, including one harboring a previously known echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion and another containing an unknown ALK fusion variant. Expression array, RNA-Seq, reverse transcription polymerase chain reaction, and direct sequencing were then conducted to confirm the rearrangements and to identify the novel fusion partner in the xenograft and/or the primary patient tumor. Finally, pharmacological studies were performed in PDX models to evaluate their responses to ALK inhibitor crizotinib. RESULTS: Two ALK-rearranged NSCLC PDX models were identified: one carried a well-known EML4-ALK variant 3a/b and the other harbored a novel huntingtin interacting protein 1 (HIP1)-ALK fusion gene. Exon 28 of the HIP1 gene located on chromosome 7 was fused to exon 20 of the ALK gene located on chromosome 2. Both cases were clinically diagnosed as squamous cell carcinoma. Compared with the other lung cancer PDX models, both ALK-rearranged models displayed elevated ALK mRNA expression. Furthermore, in vivo efficacy studies demonstrated that, similar to the EML4-ALK-positive model, the HIP1-ALK-containing PDX model was sensitive to treatment with crizotinib. CONCLUSIONS: Discovery of HIP1 as a fusion partner of ALK in NSCLC is a novel finding. In addition, the HIP1-ALK-rearranged tumor is sensitive to treatment with crizotinib in vivo, implicating HIP1-ALKas an oncogenic driver of lung tumorigenesis. Collectively, our results indicate that HIP1-ALK-positive NSCLC may benefit from clinical applications of crizotinib.


Subject(s)
Carcinoma, Non-Small-Cell Lung/genetics , DNA-Binding Proteins/genetics , Lung Neoplasms/genetics , Oncogene Proteins, Fusion/genetics , Protein Kinase Inhibitors/pharmacology , Pyrazoles/pharmacology , Pyridines/pharmacology , Receptor Protein-Tyrosine Kinases/genetics , Anaplastic Lymphoma Kinase , Animals , Carcinoma, Non-Small-Cell Lung/drug therapy , Carcinoma, Non-Small-Cell Lung/pathology , Crizotinib , DNA-Binding Proteins/antagonists & inhibitors , Female , Humans , In Situ Hybridization, Fluorescence , Lung Neoplasms/drug therapy , Lung Neoplasms/pathology , Mice , Mice, Inbred BALB C , Oncogene Proteins, Fusion/antagonists & inhibitors , RNA, Messenger/genetics , Real-Time Polymerase Chain Reaction , Receptor Protein-Tyrosine Kinases/antagonists & inhibitors , Reverse Transcriptase Polymerase Chain Reaction , Tumor Cells, Cultured
13.
PLoS One ; 8(1): e54572, 2013.
Article in English | MEDLINE | ID: mdl-23359652

ABSTRACT

Recent evidence indicates that CXCR2 signaling is crucial for cancer progression, and its antagonist SB225002 induces apoptosis in Wilms' tumor cells. Here, we investigated the effect of SB225002 on cell cycle progression and apoptosis induction in vitro, using CDDP-sensitive and -resistant OVCA cell lines with different p53 status (wild type, mutant or null). Adenovirus infection of wild-type p53 or transfection of p53 siRNA was used to over-express or knock-down p53. Cell cycle and apoptosis were determined by flow cytometry or Hoechst staining and observation of nuclear morphology. Our data demonstrated that SB225002 induced apoptosis in both wild-type and p53-deficient ovarian cancer (OVCA) cells through alternative mechanisms. SB225002 promoted mitotic catastrophe, as evidenced by the accumulation of mitotic cells with spindle abnormalities, chromosome mis-segregation, multi-polar cell division, multiple nuclei, aneuploidy/polyploidy and subsequent extensive apoptosis. SB225002-induced mitotic catastrophe appeared to be mediated by down-regulation of checkpoint kinase Chk1 and Cdk1-cyclin B activation. In cells expressing wild-type p53 (OV2008 and C13*), SB225002 increased total and phospho-Ser p53 levels, and p53 knock-down decreased SB225002-induced apoptosis, without affecting premature mitosis. These results suggest that SB225002 induces p53-dependent apoptosis, and provokes mitotic catastrophe in p53-independent manner in p53 wild-type cells. Reconstitution with wild-type P53 in P53-null SKOV3 cell attenuated SB225002-induced mitotic catastrophe, suggesting p53 prevented mitotic catastrophe induced by SB225002 in p53-deficient OVCA cells. Finally, the effect of SB225002 could not be prevented by pretreatment with CXCR2 ligand or its neutralizing antibody. The present studies demonstrate for the first time that SB225002 has dual actions in OVCA cells, inducing classic apoptosis through p53 activation and provoking mitotic catastrophe in both p53 wild-type and deficient cells by Chk1 inhibition and Cdk activation. These findings raise the possibility of SB225002 as a new candidate molecule for OVCA therapy independent of the p53 status.


Subject(s)
Mitosis/drug effects , Ovarian Neoplasms/pathology , Phenylurea Compounds/pharmacology , Tumor Suppressor Protein p53/metabolism , Antineoplastic Agents/pharmacology , Apoptosis , Base Sequence , Cell Line, Tumor , Chemokine CXCL1/metabolism , DNA Damage , DNA Primers , DNA, Complementary , Drug Resistance, Neoplasm , Female , Humans , Interleukin-8/metabolism , Ovarian Neoplasms/metabolism , Real-Time Polymerase Chain Reaction , Receptors, Interleukin-8B/metabolism
14.
Bioorg Med Chem Lett ; 21(24): 7281-6, 2011 Dec 15.
Article in English | MEDLINE | ID: mdl-22047692

ABSTRACT

An in vitro screening protocol was used to transform a systemically-distributed SCD inhibitor into a liver-targeted compound. Incorporation of a key nicotinic acid moiety enables molecular recognition by OATP transporters, as demonstrated by uptake studies in transfected cell lines, and likely serves as a critical component of the observed liver-targeted tissue distribution profile. Preclinical anti-diabetic oGTT efficacy is demonstrated with nicotinic acid-based, liver-targeting SCD inhibitor 10, and studies with a close-structural analog devoid of SCD1 activity, suggest this efficacy is a result of on-target activity.


Subject(s)
Enzyme Inhibitors/chemistry , Hypoglycemic Agents/chemistry , Hypoglycemic Agents/pharmacology , Nicotinic Acids/chemistry , Stearoyl-CoA Desaturase/antagonists & inhibitors , Administration, Oral , Animals , Cell Line , Drug Evaluation, Preclinical , Enzyme Activation/drug effects , Enzyme Inhibitors/chemical synthesis , Enzyme Inhibitors/pharmacokinetics , Enzyme Inhibitors/pharmacology , Humans , Hypoglycemic Agents/chemical synthesis , Hypoglycemic Agents/pharmacokinetics , Liver/drug effects , Liver/enzymology , Mice , Mice, Inbred C57BL , Nicotinic Acids/chemical synthesis , Nicotinic Acids/pharmacokinetics , Nicotinic Acids/pharmacology , Rats , Stearoyl-CoA Desaturase/metabolism , Structure-Activity Relationship , Tissue Distribution
15.
J Lipid Res ; 52(8): 1494-9, 2011 Aug.
Article in English | MEDLINE | ID: mdl-21642745

ABSTRACT

A positive correlation between stearoyl-CoA desaturase (SCD)1 expression and metabolic diseases has been reported in rodents and humans. These findings indicate that SCD1 is a promising therapeutic target for the chronic treatment of diabetes and dyslipidemia. The SCD1 enzyme is expressed at high levels in several human tissues and is required for the biosynthesis of monounsaturated fatty acids, which are involved in many biological processes. Liver-targeted SCD inhibitors were designed to pharmacologically manipulate SCD1 activity in the liver to avoid adverse events due to systemic inhibition. This article describes the development of a plasma-based SCD assay to assess the level of SCD inhibition, which is defined in this article as target engagement. Essentially, animals are dosed with an exogenous deuterated tracer (d7-stearic acid) as substrate, and the converted d7-oleic acid product is measured to monitor SCD1 inhibition. This study reveals that this plasma-based assay correlates with liver SCD1 inhibition and can thus have clinical utility.


Subject(s)
Acetates , Biological Assay/methods , Diabetes Mellitus/blood , Dyslipidemias/blood , Liver/metabolism , Oleic Acid/analysis , Stearoyl-CoA Desaturase/antagonists & inhibitors , Tetrazoles , Acetates/administration & dosage , Acetates/pharmacokinetics , Animals , Carbon Radioisotopes/analysis , Chromatography, High Pressure Liquid , Deuterium/analysis , Diabetes Mellitus/drug therapy , Diabetes Mellitus/physiopathology , Dyslipidemias/drug therapy , Dyslipidemias/physiopathology , Enzyme Inhibitors/administration & dosage , Enzyme Inhibitors/pharmacokinetics , Humans , Male , Mass Spectrometry , Molecular Targeted Therapy/methods , Oleic Acid/metabolism , Plasma/chemistry , Plasma/metabolism , Rats , Rats, Sprague-Dawley , Stearoyl-CoA Desaturase/metabolism , Tetrazoles/administration & dosage , Tetrazoles/pharmacokinetics
16.
J Med Chem ; 54(14): 5082-96, 2011 Jul 28.
Article in English | MEDLINE | ID: mdl-21661758

ABSTRACT

The potential use of SCD inhibitors for the chronic treatment of diabetes and dyslipidemia has been limited by preclinical adverse events associated with inhibition of SCD in skin and eye tissues. To establish a therapeutic window, we embarked on designing liver-targeted SCD inhibitors by utilizing molecular recognition by liver-specific organic anion transporting polypeptides (OATPs). In doing so, we set out to target the SCD inhibitor to the organ believed to be responsible for the therapeutic efficacy (liver) while minimizing its exposure in the tissues associated with mechanism-based SCD depletion of essential lubricating lipids (skin and eye). These efforts led to the discovery of MK-8245 (7), a potent, liver-targeted SCD inhibitor with preclinical antidiabetic and antidyslipidemic efficacy with a significantly improved therapeutic window.


Subject(s)
Acetates/chemical synthesis , Hypoglycemic Agents/chemical synthesis , Hypolipidemic Agents/chemical synthesis , Liver/enzymology , Stearoyl-CoA Desaturase/antagonists & inhibitors , Tetrazoles/chemical synthesis , Acetates/chemistry , Acetates/pharmacology , Animals , Cell Line , Diffusion , Dogs , Female , Harderian Gland/metabolism , Hep G2 Cells , Hepatocytes/metabolism , Humans , Hypoglycemic Agents/chemistry , Hypoglycemic Agents/pharmacology , Hypolipidemic Agents/chemistry , Hypolipidemic Agents/pharmacology , In Vitro Techniques , Liver-Specific Organic Anion Transporter 1 , Macaca mulatta , Male , Mice , Mice, Inbred C57BL , Microsomes/metabolism , Organic Anion Transporters/metabolism , Organic Anion Transporters, Sodium-Independent/metabolism , Rats , Rats, Sprague-Dawley , Skin/metabolism , Solute Carrier Organic Anion Transporter Family Member 1B3 , Species Specificity , Structure-Activity Relationship , Tetrazoles/chemistry , Tetrazoles/pharmacology , Tissue Distribution
17.
Bioorg Med Chem Lett ; 21(10): 2832-5, 2011 May 15.
Article in English | MEDLINE | ID: mdl-21507642

ABSTRACT

A weak antagonist of the pyrimidinergic receptor P2Y(14) containing a dihydropyridopyrimidine core was identified through high-throughput screening. Subsequent optimization led to potent, non-UTP competitive antagonists and represent the first reported non-nucleotide antagonists of this receptor. Compound 18q was identified as a 10 nM P2Y(14) antagonist with good oral bioavailability and provided sufficient exposure in mice to be used as a tool for future in vivo studies.


Subject(s)
Purinergic P2 Receptor Antagonists/chemical synthesis , Pyrimidines/chemical synthesis , Receptors, Purinergic P2/chemistry , Administration, Oral , Animals , Biological Availability , Mice , Molecular Structure , Pan troglodytes , Purinergic P2 Receptor Antagonists/chemistry , Pyrimidines/administration & dosage , Pyrimidines/chemistry , Receptors, Purinergic P2Y , Structure-Activity Relationship
18.
Bioorg Med Chem Lett ; 21(1): 479-83, 2011 Jan 01.
Article in English | MEDLINE | ID: mdl-21074991

ABSTRACT

Potent and orally bioavailable SCD inhibitors built on an azetidinyl pyridazine scaffold were identified. In a one-month gDIO mouse model of obesity, we demonstrated that there was no therapeutic index even at low doses; efficacy in preventing weight gain tracked closely with skin and eye adverse events. This was attributed to the local SCD inhibition in these tissues as a consequence of the broad tissue distribution observed in mice for this class of compounds. The search for new structural scaffolds which may display a different tissue distribution was initiated. In preparation for an HTS campaign, a radiolabeled azetidinyl pyridazine displaying low non-specific binding in the scintillation proximity assay was prepared.


Subject(s)
Azetidines/chemistry , Enzyme Inhibitors/chemistry , Pyridazines/chemistry , Stearoyl-CoA Desaturase/antagonists & inhibitors , Animals , Drug Evaluation, Preclinical , Enzyme Inhibitors/chemical synthesis , Enzyme Inhibitors/pharmacology , High-Throughput Screening Assays , Mice , Protein Binding , Pyridazines/chemical synthesis , Pyridazines/pharmacology , Stearoyl-CoA Desaturase/metabolism
19.
Bioorg Med Chem Lett ; 20(5): 1593-7, 2010 Mar 01.
Article in English | MEDLINE | ID: mdl-20137926

ABSTRACT

Elevated stearoyl-CoA desaturase (SCD) activity has been linked to a number of metabolic disorders including obesity and type II diabetes. Compound 3j, a potent SCD inhibitor (human HepG2 IC(50)=1nM) was identified from the optimization of a lead thiazole compound MF-152 with over 100-fold improvement in potency. In a 4-week chronic oral dosing at 0.2mg/kg, 3j gave a robust 24% prevention of body weight gain in mice fed on a high fat diet accompanied with an improved metabolic profile on insulin and glucose levels.


Subject(s)
Enzyme Inhibitors/chemistry , Hypoglycemic Agents/chemistry , Oxadiazoles/chemistry , Stearoyl-CoA Desaturase/antagonists & inhibitors , Thiazoles/chemistry , Administration, Oral , Animals , Dietary Fats , Enzyme Inhibitors/chemical synthesis , Enzyme Inhibitors/toxicity , Hep G2 Cells , Humans , Hypoglycemic Agents/chemical synthesis , Hypoglycemic Agents/toxicity , Mice , Mice, Inbred C57BL , Oxadiazoles/chemical synthesis , Oxadiazoles/toxicity , Stearoyl-CoA Desaturase/metabolism , Structure-Activity Relationship , Thiazoles/chemical synthesis , Thiazoles/toxicity , Weight Gain
20.
Bioorg Med Chem Lett ; 18(11): 3200-5, 2008 Jun 01.
Article in English | MEDLINE | ID: mdl-18477508

ABSTRACT

A series of quinoline/naphthalene-difluoromethylphosphonates were prepared and were found to be potent PTP1B inhibitors. Most of these compounds bearing polar functionalities or large lipophilic residues did not show appreciable oral bioavailability in rodents while small and less polar analogs displayed moderate to good oral bioavailability. The title compound was found to have the best overall potency and pharmacokinetic profile and was found to be efficacious in animal models of diabetes and cancer.


Subject(s)
Hydrocarbons, Halogenated/chemical synthesis , Hydrocarbons, Halogenated/pharmacology , Naphthalenes/chemical synthesis , Naphthalenes/pharmacology , Organophosphonates/chemical synthesis , Organophosphonates/pharmacology , Protein Tyrosine Phosphatase, Non-Receptor Type 1/antagonists & inhibitors , Animals , Combinatorial Chemistry Techniques , Diabetes Mellitus/chemically induced , Disease Models, Animal , Drug Design , Drug Screening Assays, Antitumor , Haplorhini , Hydrocarbons, Halogenated/chemistry , Mice , Molecular Structure , Naphthalenes/chemistry , Neoplasms/chemically induced , Organophosphonates/chemistry , Rats
SELECTION OF CITATIONS
SEARCH DETAIL
...